The widely reported shutdown of Central Nervous System research programs is part of a process begun long ago, and that is for drug companies to outsource riskier types of development to academia as well as smaller, less risk-averse drug companies.
In today's lesson, Kas Thomas sees this as a welcome development. "I can't think of an area that's more ripe for the entry of small, disruptive, upstart companies," Thomas writes. "The big guys had their day. They did a mediocre job. Time for some fresh blood."